Last updated: October 5, 2026
BLINCYTO generated approximately $1.13 billion in 2024 sales, up from $739 million in 2021. The 15% approximate three-year compound annual growth rate reflects broader use in acute lymphoblastic leukemia, adoption in earlier treatment settings, and the 2024 FDA expansion into consolidation therapy. Amgen’s principal commercial risks are biosimilar entry after the biologic exclusivity period, competition from CAR-T therapies and inotuzumab ozogamicin, manufacturing complexity, and the limited size of the ALL population. BLINCYTO remains a strategically important product because it is an off-the-shelf CD19-directed therapy that can be used before or instead of cellular therapy in selected patients.
What is BLINCYTO and how does blinatumomab work?
BLINCYTO is the brand name for blinatumomab, a bispecific T-cell engager that binds CD19 on B cells and CD3 on T cells. The drug redirects a patient’s T cells toward malignant B cells.
The product is administered by continuous intravenous infusion. Its commercial value comes from several attributes:
- It is an established CD19-directed therapy with substantial clinical experience.
- It does not require individualized cell manufacturing.
- It can be used in pediatric and adult B-cell precursor ALL.
- It has utility in measurable residual disease, or MRD, and consolidation settings.
- It can be used as a bridge to allogeneic hematopoietic stem-cell transplantation or other subsequent therapy.
The main operational limitation is the need for continuous infusion, inpatient monitoring in some settings, and management of cytokine release syndrome, neurologic toxicity, infections, and infusion-related complications. FDA prescribing information includes boxed warnings for cytokine release syndrome and neurologic toxicities. [1]
How have BLINCYTO sales changed over time?
Amgen reported the following global product sales:
| Year |
BLINCYTO sales |
Annual growth |
| 2021 |
$739 million |
Not applicable |
| 2022 |
$887 million |
20.0% |
| 2023 |
$1.042 billion |
17.5% |
| 2024 |
$1.127 billion |
8.2% |
Source: Amgen annual reports and 2024 Form 10-K. [2-5]
Sales increased approximately 52.5% from 2021 to 2024, equivalent to an approximate 15.1% compound annual growth rate. Growth slowed in 2024, but the product still passed the $1 billion threshold for the second consecutive year.
What drove BLINCYTO revenue growth?
The main revenue drivers were:
-
Earlier-line treatment. BLINCYTO moved beyond relapsed or refractory disease into consolidation and other earlier treatment settings.
-
MRD-directed treatment. The drug has a role in patients with MRD-positive B-cell precursor ALL, where treatment decisions have high clinical value and limited alternatives.
-
Pediatric utilization. The product is used in pediatric ALL, a segment with established clinical pathways and long treatment durations.
-
Global hematology adoption. Continued use in academic centers and transplant programs supports repeat demand.
-
Combination and sequencing strategies. BLINCYTO can be positioned before transplant, after chemotherapy, or in sequence with other CD19-directed approaches.
Amgen does not separately disclose BLINCYTO revenue by indication, treatment line, country, or payer channel. The company also does not publish a product-level gross-to-net figure for BLINCYTO. This limits precise analysis of unit volume, price increases, and geographic mix.
What FDA approvals and exclusivity periods protect BLINCYTO?
| FDA milestone |
Date |
Commercial significance |
| Initial accelerated approval for relapsed or refractory Philadelphia chromosome-negative B-cell precursor ALL |
December 3, 2014 |
Established the product in a high-unmet-need population |
| Approval for MRD-positive B-cell precursor ALL |
2018 |
Added a lower-burden, biomarker-defined treatment setting |
| Conversion and label expansions based on confirmatory data |
2016-2024 |
Reduced dependence on the original accelerated-approval indication |
| Consolidation indication for B-cell precursor ALL |
2024 |
Expanded use into earlier treatment and potentially larger patient cohorts |
FDA approved BLINCYTO in June 2024 for adults and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor ALL in the consolidation phase of a multiphase chemotherapy regimen. The action followed evidence that adding blinatumomab improved outcomes in newly diagnosed adult patients, including overall survival in the ECOG-ACRIN E1910 study. [6-8]
When does BLINCYTO lose biologic exclusivity?
BLINCYTO received its original biologics license on December 3, 2014. Under the Public Health Service Act, an FDA-approved reference biologic generally receives 12 years of reference-product exclusivity before FDA may approve a biosimilar referencing that product. The statutory reference-product exclusivity period therefore reaches its principal endpoint in December 2026, subject to FDA determinations concerning first licensure and any applicable exclusivity provisions. [9]
That date does not guarantee immediate biosimilar competition. A biosimilar applicant must complete development, submit a 351(k) application, navigate the BPCIA patent process, and obtain FDA approval. Patent claims, settlement agreements, manufacturing barriers, and commercial launch decisions can delay market entry.
What patents protect BLINCYTO?
BLINCYTO is protected through a combination of biologic exclusivity, composition and antibody-engineering claims, therapeutic-use claims, formulation claims, and manufacturing-related intellectual property.
Unlike small-molecule drugs, BLINCYTO does not have an FDA Orange Book listing. The Orange Book is primarily used for approved drug products and patent certifications under the Hatch-Waxman framework. Biologics approved under the Public Health Service Act are addressed through the Purple Book and the BPCIA. The Purple Book does not function as a complete public patent-and-exclusivity register equivalent to the Orange Book. [10]
What is the patent strength of the BLINCYTO estate?
The estate has meaningful defensive value, but its strength is difficult to reduce to a single expiration date. The most important protections are likely to involve:
- The blinatumomab molecule and related bispecific antibody architecture.
- CD19/CD3 binding configurations.
- Treatment of B-cell malignancies.
- MRD-directed use.
- Dosing schedules and treatment sequencing.
- Formulation, stability, and manufacturing processes.
Amgen acquired Micromet in 2012 for approximately $1.16 billion, bringing blinatumomab and Micromet’s BiTE platform into Amgen’s portfolio. [11] The acquisition gave Amgen platform-level know-how in addition to rights associated with BLINCYTO itself.
The commercial protection profile is stronger than a single composition-of-matter patent but weaker than the protection typically associated with a complex antibody product that has multiple independent manufacturing and device barriers. A biosimilar developer could target the molecule through the 351(k) pathway while challenging selected method, formulation, or process claims.
Are there Paragraph IV challenges or biosimilar lawsuits against BLINCYTO?
Traditional Paragraph IV certifications are not the principal challenge mechanism for BLINCYTO. Paragraph IV litigation applies to patents listed in the Orange Book for small-molecule drugs. A biosimilar applicant would instead use the BPCIA patent-exchange process, often called the patent dance, followed by patent litigation under the relevant BPCIA framework.
Through the latest public reporting reviewed for this analysis, there was no publicly disclosed FDA-approved BLINCYTO biosimilar and no established biosimilar market share. Public Amgen filings did not identify BLINCYTO as subject to a disclosed commercial biosimilar launch. [5]
What generic launch risks exist?
The immediate risk is not a conventional generic launch. It is a future biosimilar or interchangeable biologic launch after December 2026.
A first entrant could face:
- High clinical-development costs.
- Comparability requirements for a complex bispecific molecule.
- Analytical challenges involving binding, potency, aggregation, and impurity profiles.
- Specialized manufacturing and fill-finish requirements.
- Hospital formulary resistance.
- Physician preference for the originator in pediatric and transplant pathways.
- Patent litigation and potential launch-delay settlements.
The likely first market entrants would be large biologics manufacturers or specialized biosimilar companies with existing oncology infrastructure. The absence of a publicly established biosimilar competitor preserves Amgen’s current pricing and contracting position, but it does not remove the medium-term threat.
How does BLINCYTO compare with competing ALL therapies?
| Therapy |
Product type |
Main competitive advantage |
Main limitation |
| BLINCYTO |
CD19/CD3 bispecific T-cell engager |
Off-the-shelf use, MRD and consolidation utility |
Continuous infusion and cytokine-release risk |
| BESPONSA, inotuzumab ozogamicin |
CD22 antibody-drug conjugate |
Fixed-course targeted therapy |
Veno-occlusive disease risk and liver toxicity |
| TECARTUS, brexucabtagene autoleucel |
CD19 CAR-T |
Deep responses in relapsed or refractory disease |
Individualized manufacturing, high cost, intensive care requirements |
| KYMRIAH, tisagenlecleucel |
CD19 CAR-T |
Established pediatric and young-adult use |
Manufacturing time, access, and toxicity |
| AUCATZYL, obecabtagene autoleucel |
CD19 CAR-T |
Newer adult relapsed or refractory option |
Cellular-therapy logistics and cost |
| Chemotherapy and transplant |
Non-targeted or cellular treatment |
Established clinical infrastructure |
Toxicity, relapse risk, and limited tolerability |
BLINCYTO competes most directly with inotuzumab in targeted therapy and with CAR-T in relapsed or refractory disease. The products are not fully interchangeable. CAR-T may be preferred for eligible patients seeking a potentially definitive cellular therapy, while BLINCYTO has advantages where rapid availability, lower logistical complexity, MRD eradication, or pre-transplant disease control is important.
The 2024 consolidation approval changes the competitive frame. BLINCYTO is no longer dependent only on late-line salvage demand. Earlier use can create a larger and more predictable treatment base, although it also exposes the drug to broader competition from chemotherapy regimens, targeted agents, and emerging immunotherapies.
What geographic markets and manufacturing barriers affect BLINCYTO?
BLINCYTO is marketed in the United States and international markets through Amgen’s global commercial organization. Amgen reports total product sales but does not separately disclose the BLINCYTO geographic split in its annual filings. [5]
The manufacturing barrier is material. Blinatumomab is a recombinant bispecific protein requiring controlled cell-line development, purification, quality testing, potency characterization, and sterile fill-finish operations. Biosimilar developers must demonstrate a highly similar product despite the complexity of bispecific molecular structures.
Manufacturing risks include:
- Batch-to-batch potency variation.
- Aggregation and stability control.
- Protein characterization.
- Cold-chain distribution.
- Sterile injectable production.
- Validation of continuous-infusion presentation and container systems.
These factors support longer follow-on development timelines than are typical for oral generics. They also give Amgen an advantage in manufacturing reliability and hospital supply contracts.
What licensing deal brought BLINCYTO to Amgen?
Amgen acquired Micromet in 2012 for approximately $1.16 billion in cash. Micromet had developed the BiTE platform and blinatumomab. The transaction gave Amgen control of the asset and the underlying bispecific T-cell engager technology. [11]
No separate, publicly disclosed licensing payment stream is required to explain current BLINCYTO economics because Amgen owns the product following the acquisition. The transaction also created strategic value beyond BLINCYTO through Amgen’s access to the BiTE platform, which supported later pipeline programs.
What is the revenue outlook for BLINCYTO?
The base-case commercial outlook is continued growth through the late 2020s, with a lower growth rate than the 2021-2023 period.
| Period |
Expected commercial direction |
Primary driver |
| 2025-2026 |
Growth or stable expansion |
Consolidation adoption and continued MRD use |
| 2027-2028 |
Increasing competitive pressure |
Post-exclusivity biosimilar preparation and patent activity |
| 2029 onward |
Potential erosion |
Biosimilar entry, contracting pressure, and cellular-therapy substitution |
Upside factors include broader consolidation adoption, increased diagnosis and referral to specialized ALL centers, improved outpatient infusion infrastructure, and use in treatment sequencing.
Downside factors include the small underlying patient population, treatment-center capacity, adverse-event management, reimbursement pressure, CAR-T competition, and follow-on biologic entry.
A rapid revenue collapse is unlikely immediately after biologic exclusivity ends. BLINCYTO is a hospital-administered oncology biologic with complex handling and specialized use. Erosion is more likely to develop gradually unless a biosimilar demonstrates clear cost savings, obtains preferred formulary status, and solves supply and administration requirements.
What litigation and settlement issues affect BLINCYTO?
BLINCYTO’s principal future litigation risk is BPCIA litigation involving biosimilar applicants. Potential disputes may address:
- Validity and infringement of antibody or bispecific claims.
- Treatment-method claims.
- Formulation and stability patents.
- Manufacturing-process patents.
- Patent-term adjustments and extensions.
- Launch timing and pediatric or orphan exclusivity.
No publicly established BLINCYTO Paragraph IV settlement structure exists because the product is not governed by the standard Orange Book certification process. Any future settlement would likely be negotiated through the BPCIA framework and could include a delayed-entry date, licensing terms, or restrictions on the scope of launch.
Key Takeaways
- BLINCYTO sales rose from $739 million in 2021 to $1.127 billion in 2024.
- The product recorded an approximate 15.1% compound annual growth rate from 2021 through 2024.
- The 2024 consolidation approval expanded BLINCYTO into earlier-line B-cell precursor ALL treatment.
- Biologic reference-product exclusivity reaches its principal 12-year endpoint in December 2026.
- BLINCYTO is not an Orange Book product and does not face conventional Paragraph IV generic litigation.
- Future competition will come from biosimilars, CAR-T therapies, inotuzumab ozogamicin, and evolving chemotherapy regimens.
- Continuous infusion, complex protein manufacturing, and specialized oncology use may slow biosimilar erosion.
- Amgen’s acquisition of Micromet provided ownership of BLINCYTO and the BiTE platform.
- The product remains commercially durable, but growth should moderate as the market approaches the post-exclusivity period.
FAQs
How much revenue did BLINCYTO generate in 2024?
Amgen reported approximately $1.127 billion in 2024 BLINCYTO sales, compared with $1.042 billion in 2023.
Is BLINCYTO a CAR-T therapy?
No. BLINCYTO is an off-the-shelf bispecific T-cell engager. It connects CD19-positive malignant B cells with CD3-positive T cells. CAR-T therapies require collection and genetic modification of a patient’s T cells.
Does BLINCYTO have orphan-drug protection?
BLINCYTO received FDA approval for a rare hematologic malignancy indication and benefited from orphan-drug-related regulatory protection for qualifying indications. The current commercial analysis is primarily governed by biologic exclusivity, patent rights, and the BPCIA framework.
Can BLINCYTO be administered at home?
Administration may occur in outpatient or home-infusion settings for selected patients, but treatment requires continuous intravenous infusion and clinical monitoring. The appropriate setting depends on disease status, cycle, institutional protocols, and toxicity risk.
What is the largest long-term risk to BLINCYTO sales?
The largest long-term risk is combined pressure from biosimilar entry and competing CD19-directed therapies, particularly CAR-T products. The 2024 consolidation approval offsets part of that risk by expanding use into earlier treatment.
References
- U.S. Food and Drug Administration. (2024). BLINCYTO (blinatumomab) prescribing information.
- Amgen Inc. (2022). 2021 annual report.
- Amgen Inc. (2023). 2022 annual report.
- Amgen Inc. (2024). 2023 annual report.
- Amgen Inc. (2025). 2024 annual report and Form 10-K.
- U.S. Food and Drug Administration. (2014). FDA approves Blincyto to treat rare form of acute lymphoblastic leukemia.
- U.S. Food and Drug Administration. (2024). FDA approves blinatumomab for consolidation treatment of acute lymphoblastic leukemia.
- U.S. National Cancer Institute. (2024). E1910 clinical trial results for blinatumomab in newly diagnosed acute lymphoblastic leukemia.
- Public Health Service Act, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Amgen Inc. (2012). Amgen to acquire Micromet for approximately $1.16 billion.
